General MedicationsINJECTIONStandard

AMPICILLIN SODIUM

Standard Dose

EQ 125MG BASE/VIAL

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview AMPICILLIN SODIUM is listed in Drugs@FDA under application 090583 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient AMPICILLIN SODIUM Form and strength INJECTABLE;INJECTION - EQ 125MG BASE/VIAL Sponsor SAGENT PHARMS INC Submission history Latest submission status date: 2024-05-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview AMPICILLIN SODIUM is listed in Drugs@FDA under application 090583 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient AMPICILLIN SODIUM Form and strength INJECTABLE;INJECTION - EQ 125MG BASE/VIAL Sponsor SAGENT PHARMS INC Submission history Latest submission status date: 2024-05-01 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.